Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 2
1976 4
1978 2
1980 1
1986 1
1988 1
1989 1
1990 3
1994 1
1995 1
1997 2
1998 2
1999 1
2000 1
2001 5
2002 7
2003 10
2004 17
2005 10
2006 8
2007 12
2008 16
2009 17
2010 23
2011 31
2012 51
2013 58
2014 60
2015 60
2016 66
2017 54
2018 81
2019 75
2020 90
2021 81
2022 75
2023 72
2024 80
2025 70
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

957 results

Results by year

Filters applied: . Clear all
Page 1
Etiology and Management of Edema: A Review.
Koirala A, Pourafshar N, Daneshmand A, Wilcox CS, Mannemuddhu SS, Arora N. Koirala A, et al. Adv Kidney Dis Health. 2023 Mar;30(2):110-123. doi: 10.1053/j.akdh.2022.12.002. Adv Kidney Dis Health. 2023. PMID: 36868727 Review.
Diagnosis and Staging of Bladder Cancer.
Ahmadi H, Duddalwar V, Daneshmand S. Ahmadi H, et al. Hematol Oncol Clin North Am. 2021 Jun;35(3):531-541. doi: 10.1016/j.hoc.2021.02.004. Epub 2021 Apr 15. Hematol Oncol Clin North Am. 2021. PMID: 33958149 Review.
Preface.
Daneshmand S. Daneshmand S. Urol Clin North Am. 2019 Aug;46(3):xiii. doi: 10.1016/j.ucl.2019.05.002. Urol Clin North Am. 2019. PMID: 31277740 No abstract available.
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Daneshmand S, et al. Urol Oncol. 2025 May;43(5):286-296. doi: 10.1016/j.urolonc.2024.12.264. Epub 2025 Jan 15. Urol Oncol. 2025. PMID: 39818460 Free article. Review.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bögemann M, Simone G, Pieczonka CM, Casco NC, Zainfeld D, Spiegelhalder P, Xylinas E, Cahn D, Lotan Y, Murray KS, Kawahara T, Stromberg K, Martin J, Shukla A, Cutie CJ, Bertzos K, Hampras S, Sweiti H, Necchi A; SunRISe-1 Study. Daneshmand S, et al. J Clin Oncol. 2025 Nov 20;43(33):3578-3588. doi: 10.1200/JCO-25-01651. Epub 2025 Jul 30. J Clin Oncol. 2025. PMID: 40737582 Free PMC article. Clinical Trial.
Continent Cutaneous Diversion.
Pearce SM, Daneshmand S. Pearce SM, et al. Urol Clin North Am. 2018 Feb;45(1):55-65. doi: 10.1016/j.ucl.2017.09.004. Urol Clin North Am. 2018. PMID: 29169451 Review.
Reply by Authors.
Ghoreifi A, Ladi-Seyedian SS, Piatti P, Chew YC, Jara B, Sanossian L, Bhasin JM, Yamada T, Fuchs G, Bhanvadia S, Sotelo R, Hung A, Aron M, Desai M, Gill I, Daneshmand S, Liang G, Djaladat H. Ghoreifi A, et al. J Urol. 2023 May;209(5):862. doi: 10.1097/JU.0000000000003188.02. Epub 2023 Feb 23. J Urol. 2023. PMID: 36815355 No abstract available.
Outcomes of Reinduction With Nadofaragene Firadenovec.
Schmidt B, Horns JJ, Tyson MD, Daneshmand S, Linehan JA, Agarwal PK, Narayan VM, Dickstein R, Luckenbaugh AN, Lotan Y. Schmidt B, et al. J Urol. 2025 Nov;214(5):472-473. doi: 10.1097/JU.0000000000004697. Epub 2025 Aug 25. J Urol. 2025. PMID: 40852908 No abstract available.
957 results